Kenvue Inc. (NYSE:KVUE) Stock Has Average Price Target of $19.33

Kenvue Inc. (NYSE:KVUE) has earned an average recommendation of “Hold” from the thirteen ratings firms that are covering the firm, Marketbeat reports. Thirteen equities research analysts have rated the stock with a hold rating. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $19.33.

A number of research analysts recently commented on KVUE shares. Zacks Research cut Kenvue from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 7th. Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Barclays increased their price objective on shares of Kenvue from $18.00 to $19.00 and gave the stock an “equal weight” rating in a research note on Tuesday, July 21st. UBS Group cut their price target on shares of Kenvue from $20.00 to $19.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Finally, HSBC lowered their price objective on shares of Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a research report on Monday, August 10th.

Kenvue Price Performance

NYSE:KVUE opened at $19.26 on Friday. Kenvue has a 52 week low of $14.06 and a 52 week high of $20.13. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.71 and a current ratio of 1.01. The firm’s 50-day simple moving average is $18.40 and its 200 day simple moving average is $18.19. The firm has a market cap of $36.99 billion, a price-to-earnings ratio of 22.14, a P/E/G ratio of 1.79 and a beta of 0.48.

Kenvue (NYSE:KVUE) last released its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.29. The company had revenue of $3.89 billion during the quarter, compared to the consensus estimate of $3.86 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. During the same period in the previous year, the business earned $0.28 earnings per share. As a group, sell-side analysts predict that Kenvue will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 2nd. Shareholders of record on Monday, September 21st were issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 4.4%. The ex-dividend date of this dividend was Monday, September 21st. Kenvue’s dividend payout ratio (DPR) is currently 96.55%.

Key Kenvue News

Here are the key news stories impacting Kenvue this week:

• Positive Sentiment: Revenue increased 3.2% year over year to $3.89 billion, exceeding the roughly $3.86 billion consensus estimate. Management cited continued growth in Self Care and Essential Health, productivity initiatives, margin expansion and strong cash generation. Kenvue Reports Third Quarter 2026 Results
• Positive Sentiment: Reported earnings were $0.29 per share, up from $0.28 a year earlier. Zacks characterized the result as slightly ahead of its $0.28 consensus estimate, while other coverage said profit fell short of expectations, suggesting the market is focused on the exact earnings measure and guidance. Kenvue Surpasses Q3 Earnings Estimates
• Positive Sentiment: The quarterly performance represents Kenvue’s fourth consecutive quarter of net and organic sales growth, supporting management’s efforts to rebuild momentum across its consumer-health brands. Kenvue Profit, Revenue Rise as Turnaround Efforts Continue
• Neutral Sentiment: Kenvue’s results arrive as its approximately $40 billion acquisition by Kimberly-Clark approaches closing. The deal may provide strategic support, but investors remain focused on execution, integration and the turnaround’s durability. Kenvue Q3 2026 Revenue Beats as Kimberly-Clark Deal Nears Close
• Negative Sentiment: The conflicting earnings headlines indicate that profit performance did not clearly exceed investor expectations, even though revenue beat forecasts. Earlier concerns about inflation and cautious consumer spending also remain potential pressures on margins and demand. Kenvue Misses Third-Quarter Profit Expectations

Institutional Trading of Kenvue

Large investors have recently bought and sold shares of the business. CoreCap Advisors LLC increased its holdings in shares of Kenvue by 64.9% during the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock worth $29,000 after buying an additional 591 shares during the last quarter. Triumph Capital Management boosted its holdings in Kenvue by 24.2% in the third quarter. Triumph Capital Management now owns 3,060 shares of the company’s stock valued at $54,000 after acquiring an additional 596 shares during the last quarter. Montag A & Associates Inc. boosted its holdings in Kenvue by 6.3% in the first quarter. Montag A & Associates Inc. now owns 10,156 shares of the company’s stock valued at $175,000 after acquiring an additional 600 shares during the last quarter. Strive Financial Group LLC boosted its holdings in Kenvue by 5.2% in the second quarter. Strive Financial Group LLC now owns 12,263 shares of the company’s stock valued at $234,000 after acquiring an additional 609 shares during the last quarter. Finally, Mondrian Investment Partners LTD grew its position in Kenvue by 0.8% during the third quarter. Mondrian Investment Partners LTD now owns 75,868 shares of the company’s stock valued at $1,340,000 after acquiring an additional 621 shares during the period. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Company Profile

Kenvue Inc is a consumer health company that develops, markets and sells products designed to support everyday health and personal care. Its portfolio spans over-the-counter medicines, skin health and beauty, and essential health products, serving consumers through retail, e-commerce and other distribution channels.

The company’s brands include Tylenol, Motrin, Zyrtec and Benadryl in self-care; Neutrogena, Aveeno and Clean & Clear in skin health and beauty; and Listerine, Johnson’s and OGX in oral care, baby care and hair care.